| MeSH term | MeSH ID | Detail |
|---|---|---|
| Abnormalities, Drug-Induced | D000014 | 10 associated lipids |
| Abortion, Spontaneous | D000022 | 12 associated lipids |
| Abscess | D000038 | 13 associated lipids |
| Achlorhydria | D000126 | 1 associated lipids |
| Actinomycetales Infections | D000193 | 4 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Angina Pectoris | D000787 | 27 associated lipids |
| Arrhythmias, Cardiac | D001145 | 42 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (5)
- Drug Metab. Dispos. (1)
- FEMS Immunol. Med. Microbiol. (1)
- Others (5)
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Thong BY | Update on the management of antibiotic allergy. | 2010 | Allergy Asthma Immunol Res | pmid:20358021 |
| Park SJ et al. | Fulminant and Fatal Multiple Organ Failure in a 12-Year-Old Boy With Mycoplasma pneumoniae Infection. | 2012 | Allergy Asthma Immunol Res | pmid:22211173 |
| Kariyawasam HH and Scadding GK | Chronic rhinosinusitis: therapeutic efficacy of anti-inflammatory and antibiotic approaches. | 2011 | Allergy Asthma Immunol Res | pmid:21966602 |
| Siddiqui S and Brightling CE | Airways disease: phenotyping heterogeneity using measures of airway inflammation. | 2007 | Allergy Asthma Clin Immunol | pmid:20525145 |
| Xepapadaki P et al. | Atypical bacteria and macrolides in asthma. | 2008 | Allergy Asthma Clin Immunol | pmid:20525132 |
| Desrosiers M et al. | Canadian clinical practice guidelines for acute and chronic rhinosinusitis. | 2011 | Allergy Asthma Clin Immunol | pmid:21310056 |
| Wedi B et al. | Urticaria and infections. | 2009 | Allergy Asthma Clin Immunol | pmid:20066173 |
| Brož P et al. | Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. | 2012 | Allergy | pmid:22435670 |
| Igea JM and Lázaro M | Hypersensitivity reaction to clarithromycin. | 1998 | Allergy | pmid:9491242 |
| Ben-Shoshan M et al. | Anaphylactic reaction to clarithromycin in a child. | 2009 | Allergy | pmid:19222423 |
| Can C et al. | Symmetrical drug-related intertriginous and flexural exanthema induced by two different antibiotics. | Allergol Immunopathol (Madr) | pmid:23253684 | |
| Gangemi S et al. | Immediate reaction to clarithromycin. | 2001 Jan-Feb | Allergol Immunopathol (Madr) | pmid:11449533 |
| Gaig P et al. | Efficacy of the eradication of Helicobacter pylori infection in patients with chronic urticaria. A placebo-controlled double blind study. | 2002 Sep-Oct | Allergol Immunopathol (Madr) | pmid:12396958 |
| Karakaya G et al. | Determining safe antibiotics for drug hypersensitive patients with the alternative method of double-triple test. | Allergol Immunopathol (Madr) | pmid:19080798 | |
| Malheiro D et al. | Nimesulide-induced fixed drug eruption. | 2005 Sep-Oct | Allergol Immunopathol (Madr) | pmid:16287549 |
| Seitz CS et al. | Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. | Allergol Immunopathol (Madr) | pmid:21269750 | |
| Moreira A et al. | Is Helicobacter pylori infection associated with chronic idiopathic urticaria? | Allergol Immunopathol (Madr) | pmid:12890412 | |
| Drouet M et al. | [Unusual clinical form of amoxicillin allergy]. | 1996 | Allerg Immunol (Paris) | pmid:9011169 |
| Wheeldon TU et al. | The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication. | 2004 | Aliment. Pharmacol. Ther. | pmid:15191514 |
| Kositchaiwat C et al. | Low and high doses of rabeprazole vs. omeprazole for cure of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:14616168 |
| Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
| Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
| Savarino V et al. | OAM for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930908 |
| Datta S et al. | Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963080 |
| Perri F et al. | Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421877 |
| Perri F et al. | Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421878 |
| Pilotto A et al. | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421879 |
| Tepes B et al. | Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421880 |
| Calvet X et al. | What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421884 |
| Gatta L et al. | A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963079 |
| Lamouliatte H et al. | Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535872 |
| Gisbert JP et al. | Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10540045 |
| Sierra F et al. | Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. | 2013 | Aliment. Pharmacol. Ther. | pmid:23656465 |
| Borody TJ et al. | Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441468 |
| Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12786632 |
| Molina-Infante J et al. | Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. | 2015 | Aliment. Pharmacol. Ther. | pmid:25776067 |
| Nagahara A et al. | Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207518 |
| Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
| Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
| Gasbarrini A et al. | Efficacy of a multistep strategy for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632649 |
| Chan FK et al. | Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632651 |
| Pipkin GA et al. | Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768524 |
| Fischbach LA et al. | Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569109 |
| Louw JA et al. | Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768531 |
| Laine L et al. | Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768532 |
| Tomita T et al. | Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966543 |
| Vakil N et al. | Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients. | 2008 | Aliment. Pharmacol. Ther. | pmid:18774949 |
| Shokri-Shirvani J et al. | Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137738 |
| Axon AT et al. | Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042977 |
| Labenz J et al. | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042978 |
| Labenz J et al. | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042979 |
| Calvet X et al. | One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12144575 |
| Di Caro S et al. | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876707 |
| Vakil N et al. | Seven-day therapy for Helicobacter pylori in the United States. | 2004 | Aliment. Pharmacol. Ther. | pmid:15225176 |
| Wu JC et al. | Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876709 |
| Basset C et al. | Helicobacter pylori infection: anything new should we know? | 2004 | Aliment. Pharmacol. Ther. | pmid:15335411 |
| Mason J et al. | The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876711 |
| Georgopoulos SD et al. | Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876712 |
| Elizalde JI et al. | Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876713 |
| Savarino V et al. | Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:9892878 |
| Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
| Bazzoli F et al. | Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663723 |
| Pozzato P et al. | Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663724 |
| Goh KL et al. | Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? | 1997 | Aliment. Pharmacol. Ther. | pmid:9663838 |
| Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
| Kolkman JJ et al. | Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663840 |
| Pilotto A et al. | The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233191 |
| Miyaji H et al. | Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. | 1997 | Aliment. Pharmacol. Ther. | pmid:9663841 |
| Wong BC et al. | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. | 2000 | Aliment. Pharmacol. Ther. | pmid:11069326 |
| Lionetti E et al. | Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:17032283 |
| Laurent J et al. | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 2001 | Aliment. Pharmacol. Ther. | pmid:11683693 |
| O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
| Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
| Goodgame RW et al. | Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736715 |
| Sheu BS et al. | The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755841 |
| You JH et al. | Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421876 |
| Cammarota G et al. | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971300 |
| Pilotto A et al. | Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971305 |
| Gudjonsson H et al. | High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9845401 |
| Cammarota G et al. | High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. | 2004 | Aliment. Pharmacol. Ther. | pmid:15043520 |
| Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
| Tam YH et al. | Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803605 |
| Sengupta S et al. | Effect of oral clarithromycin on gall-bladder motility in normal subjects and those with gall-stones. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803607 |
| Ford AC et al. | Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. | 2007 | Aliment. Pharmacol. Ther. | pmid:17944741 |
| Pilotto A and Malfertheiner P | Review article: an approach to Helicobacter pylori infection in the elderly. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929385 |
| Osato MS et al. | Comparative efficacy of new investigational agents against Helicobacter pylori. | 2001 | Aliment. Pharmacol. Ther. | pmid:11284777 |
| Xiao SD et al. | A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. | 2001 | Aliment. Pharmacol. Ther. | pmid:11136281 |
| Nista EC et al. | Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969089 |
| Wong WM et al. | Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16423001 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| Klok RM et al. | Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966514 |
| Tsuzuki T et al. | Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966545 |
| Ott EA et al. | Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882244 |
| Isomoto H et al. | High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848631 |
| Gisbert JP et al. | Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. | 2005 | Aliment. Pharmacol. Ther. | pmid:16268980 |
| Ellenrieder V et al. | Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9701524 |
| Miwa H et al. | Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? | 2003 | Aliment. Pharmacol. Ther. | pmid:12823158 |
| Lim AG et al. | Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. | 1997 | Aliment. Pharmacol. Ther. | pmid:9218079 |
| Armuzzi A et al. | The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. | 2001 | Aliment. Pharmacol. Ther. | pmid:11148433 |
| McNulty CA et al. | Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? | 2012 | Aliment. Pharmacol. Ther. | pmid:22469191 |